A trial to investigate the effect of serial intrasilicone oil bevacizumab injections (1.25 mg/0.05 mL) on visual acuity (VA) and anatomic outcomes in eyes undergoing proliferative vitreoretinopathy (PVR)-related retinal detachment (RD) repair
Latest Information Update: 10 May 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Proliferative vitreoretinopathy
- Focus Therapeutic Use
Most Recent Events
- 10 May 2016 New trial record